EAS Newsletter May 9, 2023
2023 Update on Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
We are glad to inform you that our Updated EAS statement on homozygous familial hypercholesterolaemia: driving better care of patients globally has been just published. It’s available in Open Access, and it’s a must to read.
Since 2014, when the last consensus on this topic was published, changes in the landscape regarding screening, diagnosis, and management of HoFH have made necessary a new consensus statement.
The recommendations of this new EAS statement are fundamental to improving HoFH care in all regions of the world. Education programmes to improve awareness, screening programmes to improve early identification, and registries linked to outcome are all essential to improve health policy globally.
EAS President, Professor Kausik K. Ray, Imperial College London, UK commented: ‘The EAS has led the way over the last decade to reduce the burden of cardiovascular disease resulting from HoFH. This latest update of the consensus paper brings under one umbrella all available data on genetics, implications of current practice and clinical management. We have worked with policy groups within the European Union and World Heart Federation to push forward screening for inherited lipid disorders including in childhood. We look forward to disseminating the current consensus globally and working with stakeholders globally to implement our recommendations.’
This consensus panel was co-chaired by Dr Marina Cuchel (Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA), Prof Frederick J. Raal (University of the Witwatersrand, Parktown, Johannesburg, South Africa) and Prof Robert A. Hegele (Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada). The panel comprised over 20 experts from across the globe with expertise in the management of familial hypercholesterolaemia.
Here you will find it and learn more about the central messages from the leading panel members:To publications from the Consensus Position Paper InitiativeTo Updated EAS statement
Two weeks left until we meet in Mannheim
#EASCongress2023 is starting in two weeks. The event will be held on May 21-24 in Mannheim. We are delighted to have the opportunity to bring together numerous leaders and innovators in our field, all in one place and at the same time.
Don’t miss out on the chance to join us and stay up-to-date with the latest advances in our field.
Register now by following the links below and be a part of this fantastic opportunity to exchange knowledge and shape the future of our field.
Registration is still open for both onsite and online attendance.
Join us for the EAS Lipotoxicity Course, June 8-9
The Lipotoxicity course will provide a unique opportunity to explore the latest advancements in a narrow field. As on-site conferences remain one of the most effective ways to enhance skills and exchange knowledge, we highly recommend attending this event to stay up-to-date with the latest developments.
Register now to ensure your attendance and join us in Prague, June 8-9.To registrationTo programme